“Most people with cardiovascular disease are taking blood thinner medications such as Plavix but it turns out that 30 to 40 percent have a very common gene variant that reduces the effectiveness of these medications. That places them at a higher risk for developing blood clots after a procedure such as stenting,” said principal investigator Doctor Colin M. Barker, assistant professor of cardiology at The University of Texas Health Science Center at Houston (UTHealth) and an attending physician at Memorial Hermann Heart & Vascular Institute.
Barker and researchers at the Scripps Translational Science Institute in La Jolla, enrolled 41 patients. In the 20 who had the gene variant, doubling the dose of the blood thinner clopidogrel (Plavix) resulted in a significant reduction in platelet reactivity (the process that leads to the formation of blood clots).
“This is an important study because the discovery moves the field of personalized medicine and patient-centered care a step further,” Barker said. “We are now studying this in larger, randomized, controlled clinical trials.”
MEDICA.de; Source: University of Texas Health Science Center at Houston